Holen Sie sich die Stockscreener-App
3.0619
10.69%
0.3019
Handel nachbörslich:
2.90
-0.1619
-5.29%
Schlusskurs vom Vortag:
$2.76
Offen:
$2.46
24-Stunden-Volumen:
8.06M
Relative Volume:
4.82
Marktkapitalisierung:
$299.78M
Einnahmen:
$40.52M
Nettoeinkommen (Verlust:
$-160.06M
KGV:
-1.6257
EPS:
-1.8834
Netto-Cashflow:
$-165.85M
1W Leistung:
+24.19%
1M Leistung:
+4.98%
6M Leistung:
+27.29%
1J Leistung:
+97.10%
1-Tages-Spanne:
$2.41
$3.40
1-Wochen-Bereich:
$2.41
$3.40
52-Wochen-Spanne:
$1.5646
$4.5372
Editas Medicine Inc Stock (EDIT) Company Profile
Firmenname
Editas Medicine Inc
Sektor
Branche
Telefon
617-401-9000
Adresse
11 HURLEY ST., CAMBRIDGE, MA
Compare EDIT vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
3.0619 | 270.22M | 40.52M | -160.06M | -165.85M | -1.8834 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-16 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-12-13 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-12-13 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-13 | Herabstufung | Truist | Buy → Hold |
| 2024-12-11 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-11-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-11-04 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-08-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-05-09 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-24 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-10-18 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-10-17 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-29 | Hochstufung | Stifel | Hold → Buy |
| 2023-06-12 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-13 | Eingeleitet | Citigroup | Neutral |
| 2022-12-06 | Fortgesetzt | Credit Suisse | Neutral |
| 2022-11-18 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-11-18 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-09-29 | Eingeleitet | BofA Securities | Neutral |
| 2021-10-19 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2021-09-24 | Eingeleitet | Stifel | Hold |
| 2021-09-10 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-08-09 | Hochstufung | Truist | Hold → Buy |
| 2021-08-05 | Hochstufung | Evercore ISI | Underperform → Outperform |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-04-16 | Eingeleitet | Goldman | Sell |
| 2021-03-22 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-01 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-02-26 | Herabstufung | Truist | Buy → Hold |
| 2021-01-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-01-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-12-10 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-11-03 | Eingeleitet | Robert W. Baird | Underperform |
| 2020-06-18 | Fortgesetzt | SunTrust | Buy |
| 2020-02-21 | Eingeleitet | Wells Fargo | Equal Weight |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-10-10 | Eingeleitet | Guggenheim | Neutral |
| 2018-09-21 | Eingeleitet | Raymond James | Outperform |
| 2018-05-15 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-02-13 | Eingeleitet | CLSA | Underperform |
| 2018-01-23 | Hochstufung | SunTrust | Hold → Buy |
| 2017-07-14 | Eingeleitet | SunTrust | Hold |
| 2017-03-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-08-10 | Hochstufung | Jefferies | Hold → Buy |
| 2016-06-02 | Eingeleitet | Jefferies | Hold |
| 2016-02-29 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-02-29 | Eingeleitet | JP Morgan | Neutral |
| 2016-02-29 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Editas Medicine Inc Aktie (EDIT) Neueste Nachrichten
EDIT: Financing Efforts Advance with Recent Offering - GuruFocus
Editas Medicine (EDIT) Shares Drop Following Stock Offering Anno - GuruFocus
Editas Medicine stock dips on proposed equity offering - MSN
Editas Medicine prices $125M stock offering with warrants By Investing.com - Investing.com Australia
Editas reports preclinical data for gene editing treatment - Investing.com UK
Editas Medicine prices $125M stock offering with warrants - Investing.com
Editas Medicine stock tumbles on stock offering announcement By Investing.com - Investing.com Nigeria
Editas offering links warrant window to cholesterol trial results - Stock Titan
Editas Medicine stock tumbles on stock offering announcement - Investing.com
Editas Medicine (NASDAQ: EDIT) halts sales under TD Cowen ATM prospectus - Stock Titan
Editas Medicine Proposes Public Stock Offering; Shares Fall Pre-Bell - Moomoo
Editas Medicine (EDIT) Showcases Promising Preclinical Findings for EDIT-401 - GuruFocus
Editas Medicine (EDIT) Initiates Public Offering of Common Stock - GuruFocus
Editas Medicine launches public offering of stock and warrants - Investing.com
Editas reports preclinical data for gene editing treatment By Investing.com - Investing.com Australia
Editas Medicine (NASDAQ: EDIT) offers common shares, pre-funded warrants and detachable warrants - Stock Titan
EDIT-401 gene-editing data and trial path at Editas Medicine (NASDAQ: EDIT) - Stock Titan
Editas Medicine Announces Proposed Public Offering - Caledonian Record
Gene-editing firm Editas moves to sell new shares and warrants - Stock Titan
Editas Medicine Presents EDIT-401 Preclinical Data Showing ~90% Cuts in LDL-C, Lp(a), and ApoB; CTN Planned Mid-2026 - TradingView
Editas Medicine Announces Promising Preclinical Results for EDIT-401, Showcasing Significant Reductions in LDL-C, Lp(a), and ApoB - Quiver Quantitative
One-shot gene edit slashes multiple cholesterol drivers in animal tests - Stock Titan
Editas Medicine stock (US28106W1036): Recent clinical updates keep investors focused - AD HOC NEWS
Editas Medicine Unveils New Data on EDIT-401 for Hyperlipidemia - Intellectia AI
EDIT's Q1 loss narrower than expected, pipeline in focus - MSN
Analyst Forecasts Just Became More Bearish On Editas Medicine, Inc. (NASDAQ:EDIT) - Moomoo
JonesTrading Maintains Editas Medicine(EDIT.US) With Buy Rating, Raises Target Price to $8 - Moomoo
EDIT Stock Price, Quote & Chart | EDITAS MEDICINE INC (NASDAQ:EDIT) - ChartMill
Editas Medicine Reports Durable ≥90% LDL-C Reduction With Single Dose of EDIT-401 in Preclinical Hyperlipidemia Data at ASGCT 2026 - Minichart
Editas Medicine stock (US28106W1036): EDIT-401 shows 90% LDL reduction in preclinical study - AD HOC NEWS
Editas Medicine (EDIT) Advances Gene Editing Candidate for Hyper - GuruFocus
Editas Medicine presents preclinical data on EDIT-401 therapy By Investing.com - Investing.com Australia
Editas Medicine presents preclinical data on EDIT-401 therapy - Investing.com UK
Editas Showcases Promising EDIT-401 Hyperlipidemia Preclinical Data - TipRanks
EDIT-401 preclinical data show ≥90% LDL-C drop in primates (EDIT) - Stock Titan
Editas Reports ≥90% Mean LDL-C Reduction with Single EDIT-401 Dose in NHPs; Durable ~6 Months - TradingView
Editas Medicine Reports New Preclinical Data Demonstrating - GlobeNewswire
Gene editing test from Editas cuts LDL cholesterol 90% in monkeys - Stock Titan
Editas Medicine presents new in vivo gene editing data on EDIT-401 at TIDES USA 2026 Meeting - Traders Union
Editas Medicine unveils cardiovascular research at ASGCT and TIDES USA events - Traders Union
Some Analysts Just Cut Their Editas Medicine, Inc. (NASDAQ:EDIT) Estimates - Yahoo Finance
Editas Medicine (NASDAQ:EDIT) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Editas Medicine Inc. (EDIT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Analysts Offer Insights on Healthcare Companies: Brookdale Senior Living (BKD), Tempus AI, Inc. Class A (TEM) and Editas Medicine (EDIT) - The Globe and Mail
Earnings Update: Editas Medicine, Inc. (NASDAQ:EDIT) Just Reported And Analysts Are Boosting Their Estimates - simplywall.st
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
BofA Securities Maintains Editas Medicine(EDIT.US) With Sell Rating - Moomoo
RBC Capital Maintains Editas Medicine(EDIT.US) With Hold Rating, Maintains Target Price $4 - Moomoo
EDIT's Q1 Loss Narrower Than Expected, Pipeline in Focus - The Globe and Mail
Editas Medicine posts first quarter 2026 results and provides business update - Traders Union
A Quick Look at Today's Ratings for Editas Medicine(EDIT.US), With a Forecast Between $3 to $4 - Moomoo
Finanzdaten der Editas Medicine Inc-Aktie (EDIT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Editas Medicine Inc-Aktie (EDIT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Parison Amy | SVP, Chief Financial Officer |
Mar 03 '26 |
Sale |
2.02 |
474 |
957 |
15,434 |
| Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER |
Mar 03 '26 |
Sale |
2.02 |
749 |
1,513 |
68,028 |
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):